MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product...(supervising MedImmune's rapidlyexpanding...)

Date:2/7/2008

supervising MedImmune's rapidly expanding product portfolio, particularly in the areas of cancer and inflammatory disease research as well as translational sciences. Prior to joining MedImmune, Dr. Kiener spent 18 years with Bristol-Myers Squibb's (BMS) Pharmaceutical Research Division, finally holding the position of director, immunology, inflammation, pulmonary and oncology drug discovery at the BMS facility in Princeton, NJ. Before his employment at Bristol-Myers, Dr. Kiener previously served as assistant professor at the University of North Texas/Texas College of Osteopathic Medicine's Department of Anatomy; as a research associate at the Department of Biochemistry, University of Massachusetts (Amherst); and as a postdoctoral research assistant, Medical Research Council, Sir William Dunn School of Pathology, University of Oxford. Dr. Kiener holds a bachelor of science degree with honors in chemistry from Lancaster University, Lancaster, UK, and a doctorate of philosophy in biochemistry from the Sir William Dunn School of Pathology, Oxford University, Oxford, UK.

Ms. Katy Strei, who has been promoted from senior director, corporate capabilities to vice president, people and organization development within MedImmune's human resources function, brings nearly 20 years strategic leadership and talent development experience to her role at MedImmune. She is responsible for the strategy and implementation of the company's key people processes and programs, including performance management, succession planning and leadership development. In addition she oversees training and development initiatives. Prior to joining MedImmune in 2005, Ms. Strei served as director of executive development for Fannie Mae and had served in various training and organization development roles at ManorCare Health Services and Sallie Mae. She holds an undergraduate degree in sociology from Lawrence University; a master's in organization development from American University; and complete
'/>"/>

SOURCE MedImmune Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. MedImmune Submits Biologics License Application to FDA for Motavizumab
2. MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas
3. MedImmune Announces Seven Key Promotions and New Hires
4. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
5. MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
6. MedImmune Recognized by Local Volunteer Organization for Its Employees Exceptional Commitment to Community Service within Montgomery County
7. MedImmune Celebrates Opening of New Pilot Lab at Gaithersburg Headquarters
8. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
9. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
10. Anavex strengthens Board of Directors
11. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities